Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease
Authors:
- Sotirios TsimikasSTSotirios Tsimikas
- 1 October 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 17 (5) , 502-509
Abstract
The aim of this article is to review, analyze and interpret the growing body of evidence on circulating oxidized low-density lipoprotein and its relationship to diagnosis and prognosis of cardiovascular disease. Previous studies focused on indirect measures of oxidative stress such as susceptibility of low-density lipoprotein to oxidation and measurement of autoantibodies to oxidized low-density lipoprotein. The generation of monoclonal antibodies recognizing distinct oxidation-specific epitopes has allowed the development of sensitive and specific assays to measure circulating oxidized low-density lipoprotein. Recent work in human populations has demonstrated that circulating oxidized low-density lipoprotein is associated with preclinical atherosclerosis, coronary and peripheral arterial atherosclerosis, acute coronary syndromes and vulnerable plaques. Several studies have also suggested that elevated levels of oxidized low-density lipoprotein are a prognostic indicator of cardiovascular outcomes. In addition, it has been shown that lipoprotein(a) is the primary carrier of oxidized phospholipids in the circulation of humans, suggesting additional mechanisms through which lipoprotein(a) may be pro-atherogenic. Research on circulating oxidized low-density lipoprotein biomarkers is rapidly accelerating and providing novel insights into the pathophysiology of cardiovascular disease. Future studies will further assess the clinical utility of oxidized low-density lipoprotein biomarkers by determining their prognostic value in the diagnosis and prognosis of cardiovascular disease and will also evaluate the relative merit of specific assays by performing comparative studies.Keywords
This publication has 52 references indexed in Scilit:
- Oxidized Low-Density Lipoprotein in Children With Familial Hypercholesterolemia and Unaffected SiblingsJACC, 2006
- Persistent High Levels of Plasma Oxidized Low-Density Lipoprotein After Acute Myocardial Infarction Predict Stent RestenosisArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemiaAtherosclerosis, 2006
- Plasma levels of oxidized-low-density lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaquesAtherosclerosis, 2006
- Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable anginaAmerican Heart Journal, 2005
- Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stentingAmerican Heart Journal, 2005
- Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Act Local, Act Global⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.JACC, 2005
- Circulating Oxidized Low-Density Lipoprotein and Its Association With Carotid Intima-Media Thickness in Asymptomatic Members of Familial Combined Hyperlipidemia FamiliesArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery diseaseAtherosclerosis, 2004